1. 127P Phase I study of fianlimab: A human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced NSCLC. (December 2022) Authors: Cho, B.C.; Dy, G.; Kim, T.M.; Sarker, D.; Hamid, O.; Williamson, S.; Sang-We, K.; Hatim, H.; Chen, S.; Mani, J.; Jankovic, V.; Paccaly, A.J.; Masinde, S.; Lowy, I.; Brennan, L.; Gullo, G. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 187P Phase I/II study of the oral CCR4 antagonist, FLX475, as monotherapy and in combination with pembrolizumab in advanced cancer. (December 2022) Authors: Lin, C-C.; Kim, T.M.; Desai, P.; Lee, K.H.; Feng, Y-H.; Ngamphaiboon, N.; Kim, S-B.; Yang, M-H.; Muzaffar, J.; Chmielowski, B.; Swiecicki, P.L.; Bowyer, S.E.; Brahmer, J.R.; Chisamore, M.; Goyal, R.; Nasrah, N.; Ho, W.; Cho, B.C. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 3100 Phase Ib/II study of the pan-cyclin-dependent kinase (CDK) inhibitor roniciclib (BAY 1000394) in combination with chemotherapy as first-line therapy in subjects with extensive disease small cell lung cancer (ED-SCLC). (September 2015) Authors: Cho, B.C.; Dy, G.K.; Govindan, R.; Kim, D.W.; Pennell, N.A.; Zalcman, G.; Besse, B.; Nogai, H.; Rajagopalan, P.; Ocker, M.; Barlesi, F. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S634 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. EP-1073: The usefulness of 18F-FDG PET and PET-based considerations in locally advanced nasopharyngeal cancer. (April 2016) Authors: Yoon, H.I.; Kim, K.H.; Lee, J.; Roh, Y.H.; Yun, M.; Cho, B.C.; Lee, C.G.; Keum, K.C. Journal: Radiotherapy and oncology Issue: Volume 119(2016)Supplement 1 Page Start: S516 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. First-in-human safety, pharmacokinetics, and preliminary efficacy of TPX-0022, a novel inhibitor of MET/SRC/CSF1R in patients with advanced solid tumors harboring genetic alterations in MET. (October 2020) Authors: Hong, D.; Bazhenova, L.; Cho, B.C.; Sen, S.; Ponz-Sarvise, M.; Heist, R.; Zimmerman, Z.; Le, X.; Xuan, D.; Junming, Z.; Lee, J. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC). (October 2022) Authors: Cho, B.C.; Lin, J.; Camidge, D.R.; Velcheti, V.; Solomon, B.; Lu, S.; Lee, K.H.; Kim, S.W.; Kao, S.; Diadziuskzko, R.; Beg, M.; Nagasaka, M.; Felip, E.; Besse, B.; Springfeld, C.; Popat, S.; Wolf, J.; Trone, D.; Stopatschinskaja, S.; Drilon, A. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. PO-0995: Development of cylindrical applicator for CNT based miniature electronic brachytherapy source. (April 2018) Authors: Kim, H.J.; Lee, J.H.; Jeong, C.Y.; Kwak, J.W.; Cho, S.O.; Cho, B.C.; Lee, S.W. Journal: Radiotherapy and oncology Issue: Volume 127(2018)Supplement 1 Page Start: S554 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial. (October 2022) Authors: Hong, D.; Shergill, A.; Bazhenova, L.; Cho, B.C.; Heist, R.; Moreno, V.; Falchook, G.S.; Nagasaka, M.; Cassier, P.; Besse, B.; Kim, D.W.; Yoon, S.; Le, X.; Zhao, T.; Atwal, S.; Park, E.; Lee, J. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S72 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. The impact of dermatological toxicities of anti‐cancer therapy on the dermatological quality of life of cancer patients. (13th February 2012) Authors: Ra, H.S.; Shin, S.J.; Kim, J.H.; Lim, H.; Cho, B.C.; Roh, M.R. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 27:Number 1(2013:Jan.) Page Start: e53 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1). (October 2022) Authors: Besse, B.; Springfeld, C.; Baik, C.; Hervieu, A.; Solomon, B.; Moreno, V.; Bazhenova, L.; Goto, K.; Kim, Y.C.; Lu, S.; Sun, M.; Trone, D.; Thamake, S.; Cho, B.C.; de Langen, A.; Popat, S.; Wolf, J.; Moro-Sibilot, D.; Fang, J.; Drilon, A. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S75 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗